Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status

Table 5 Correlation between LPC levels and the examined parameters in various subgroups

subgroup	Δ FD vs. LPC	HPO¹ vs. LPC	CRP¹ vs. LPC	ECF vs. LPC	albumin¹ vs. LPC
breast (n = 17)	r = 0.2646	-0.811	-0.473	-0.666	0.325
	p = 0.3047	0.0000*	0.0537	0.0035*	0.196
prostate (n = 6)	-0.347	-0.257	-0.507	-0.534	0.638
	0.5	0.658	0.297	0.275	0.175
lung (n = 5)	-0.291	-0.7	0.000	0.51	-0.7
	0.634	0.233	1.000	0.38	0.233
lymphoma (n = 8)	0.777	-0.595	-0.655	-0.731	0.401
	0.0233*	0.102	0.0716	0.0394*	0.29
GIT (n = 12)	0.382	0.055	-0.567	-0.514	0.653
	0.22	0.852	0.0512	0.0873	0.0203*
other (n = 11)	0.258	-0.482	-0.397	-0.48	0.693
	0.443	0.124	0.21	0.135	0.0321*
Δ FD>10%loss (n = 15)	0.5315	-0.136	-0.575	-0.6612	0.386
	0.0414*	0.62	0.0241*	0.0153*	0.15
BMI ≤ 21 (n = 9)	0.422	-0.833	0.008	-0.828	0.51
	0.258	0.0019*	0.948	0.0059*	0.138
CRP > 1 (n = 22)	0.337	-0.301	-0.427	-0.4691	0.33
	0.125	0.17	0.0467*	0.0276*	0.131
HPO ≥ 500 (n = 18)	0.014	-0.29	-0.519	-0.318	0.384
	0.956	0.238	0.0269*	0.198	0.114
alb. < 3,5 (n = 10)	0.217	-0.345	-0.713	-0.583	0.428
	0.546	0.309	0.0186*	0.0769	0.199

¹non-normal distribution; correlation tests performed with Spearman rank correlation test
* significant correlation (p < 0.05)
Upper number in cells corresponds to correlation coefficient r of respective pair analysis, lower number corresponds to p (as displayed in first cell)

ISSN: 1476-511X